← Eichor
Study identifier: NCT02171845 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

Condition: Medical Termination of Pregnancy · Voluntary Termination of Pregnancy  ·  Sponsor: Centre Hospitalier Universitaire Dijon

PhaseN/A
Planned participants30
Who can joinMale, 10 Weeks to 37 Weeks
Healthy volunteersNo

About this study

This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. The tissue analysed will principally be the gonads, other somatic tissue will also be systematically harvested in parallel (liver and psoas muscle) for control purposes. The gonads will be subjected to molecular biology analyses destined to quantify the expression of transposons and their inhibitors.

This description comes directly from the study's public registry record.

Talk to the study team

Patricia FAUQUE  ·  3.80.29.50.31  ·  patricia.fauque@chu-dijon.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de DIJONDijon, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02171845